[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-adenocarcinoma-non-resectable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-adenocarcinoma-non-resectable":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100629954","phase-1-a-first-in-human-study-to-evaluate-implantable-iontophoresis-chemotherapy-delivery-device-with-gemcitabine-once-weekly-or-twice-weekly-in-participants-with-pancreatic-cancer-100629954",false,"NCT07481383","A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer","A First-in-Human, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ACT Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine (ACT-IOP-003) Once Weekly or Twice Weekly Following First-Line Systemic Chemotherapy in Participants With Nonresectable Pancreatic Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.\n* Diagnosis of nonmetastatic, nonresectable pancreatic adenocarcinoma as evident on initial study. screening computed tomography (CT) or magnetic resonance imaging (MRI) or previous scan within the last 12 weeks.\n* Initial diagnosis of borderline or locally advanced pancreatic adenocarcinoma confirmed as being nonresectable at the time of exploratory laparoscopic and\u002F or open surgery.\n* Previously received prior standard of care\u002Fneoadjuvant chemotherapy of FOLFIRINOX or GEM Abraxane for their current diagnosis of pancreatic cancer.\n\nExclusion Criteria:\n\n* Current pancreatitis classified as severe or critical.\n* Prior radiation treatment as part of standard of care\u002Fneoadjuvant treatment for pancreatic cancer.\n* Evidence of metastatic pancreatic cancer or any other type of cancer upon screening of through CT\u002FMRI.\n* Any medical history of past or present cardiovascular disease related to heart function.\n* Any metal implants.\n\nNote: Other inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study is being done to find out if delivering gemcitabine using the ACT-IOP-003 device directly to the area where the tumor is in the pancreas is safe and tolerable.\n\nThe main questions the study aims to answer are:\n\n* Is ACT-IOP-003 safe and tolerable when given to patients with nonmetastatic, locally advanced, nonresectable pancreatic cancer.\n* How much study drug (gemcitabine) is found in the blood before and after treatment.\n* If the tumor responds to treatment.\n* If the gemcitabine side effects are less than seen when delivered intravenously (IV).\n\nStudy participants will:\n\n* Have the study device surgically placed on the pancreas at the beginning of the study.\n* Complete 8 weeks of treatment with a 4 week screening period and 12 weeks of follow-up for a total of 24 weeks of participation in the study.\n* Give blood, urine, and stool samples to monitor safety and determine how much of the study drug (gemcitabine) is in the blood.\n* Have imaging (CT) done at least three times during the study.",[26],"Pancreatic Adenocarcinoma Non-resectable",[28,29,30],"Pancreatic Cancer","Non-resectable Tumor","Solid Tumor","RECRUITING","2026-04-29",{"date":34,"type":35},"2026-05-01","ACTUAL",{"date":37,"type":35},"2026-03-11",{"date":39,"type":20},"2027-11-01",{"name":41,"class":42},"Continuity Biosciences, LLC","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100479523","preopanc-4-implementation-program-for-locally-advanced-pancreatic-cancer-100479523","NCT05524090","PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer","Nationwide Implementation Program for Optimal Multidisciplinary Management and Resection of Locally Advanced Pancreatic Cancer (PREOPANC-4)","PREOPANC-4","Inclusion Criteria:\n\n* Age 18 years or older\n* Pathology-confirmed (LAPC)\\*\n* CT-based non-progressive disease (RECIST criteria) after at least 4 months of systemic chemotherapy (\\[m\\]FOLFIRINOX \u002F gemcitabine-nab-paclitaxel).\n\nExclusion Criteria:\n\n* Metastatic pancreatic cancer prior to induction chemotherapy.\n\n  * According to the Dutch Pancreatic Cancer Group (DPCG) definition: \\>90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and\u002For hepatic artery) and\u002For portovenous involvement of either \\>270 degrees or occlusion.",{"count":52,"type":20},223,"60 Months","OBSERVATIONAL","A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021\\[7\\]-2030\\[6\\]), including a multidisciplinary training program by the four leading international expert centers.\n\nThe PREOPANC-4 project aims a safe and patient-centered implementation of the international standards of excellence for LAPC (surgery) in the Netherlands.",[28,57,26,58],"Locally Advanced Pancreatic Adenocarcinoma","Chemotherapy Effect",[60,61,62,63,64],"Nationwide implementation International Best-Practice","The Netherlands","International Best-Practice","Patient Selection","Patient-centered","2022-08-29",{"date":67,"type":35},"2022-09-01",{"date":69,"type":35},"2021-07-01",{"date":71,"type":20},"2030-12-31",{"name":73,"class":74},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",1]